1. Home
  2. CHW vs DNA Comparison

CHW vs DNA Comparison

Compare CHW & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Global Dynamic Income Fund

CHW

Calamos Global Dynamic Income Fund

HOLD

Current Price

$8.08

Market Cap

517.9M

Sector

Finance

ML Signal

HOLD

Logo Ginkgo Bioworks Holdings Inc.

DNA

Ginkgo Bioworks Holdings Inc.

HOLD

Current Price

$8.96

Market Cap

607.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHW
DNA
Founded
2007
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
517.9M
607.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CHW
DNA
Price
$8.08
$8.96
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
$10.50
AVG Volume (30 Days)
195.2K
1.1M
Earning Date
01-01-0001
02-25-2026
Dividend Yield
9.27%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$180,606,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.07
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.07
$5.00
52 Week High
$6.54
$17.58

Technical Indicators

Market Signals
Indicator
CHW
DNA
Relative Strength Index (RSI) 60.80 48.05
Support Level $7.86 $8.65
Resistance Level $8.27 $9.61
Average True Range (ATR) 0.12 0.79
MACD -0.01 -0.03
Stochastic Oscillator 56.10 50.00

Price Performance

Historical Comparison
CHW
DNA

About CHW Calamos Global Dynamic Income Fund

Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities, and alternative investments.

About DNA Ginkgo Bioworks Holdings Inc.

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Share on Social Networks: